SCHEMBL14770474

SCHEMBL14770474

CSc1ccc(C(O)c2nc3cc(F)ccc3[nH]2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLKL Q8NB16 2/20 0.48
ALPL P05186 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
ALOX5 P09917 2/20 0.36
SCN10A Q9Y5Y9 1/20 0.35
MAPK14 Q16539 4/20 0.35
GCGR P47871 3/20 0.35
MAPK13 O15264 2/20 0.35
MAPK12 P53778 2/20 0.35
MAPK11 Q15759 2/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
MATK P42679 1/20 0.35
FRK P42685 1/20 0.35
MAPK9 P45984 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770477 0.85 MLKL (0.66) MLKLALPLALPIALPGSCN10A
SCHEMBL12065617 0.85 ALPL (0.44) MLKLALPLALPIALPG
SCHEMBL14770470 0.82 MLKL (0.48) MLKLALPLALPIALPGBRD4
SCHEMBL12065631 0.81 MLKL (0.52) MLKLALPLALPIALPGBRD4
SCHEMBL12065613 0.81 ALPL (0.47) MLKLALPLALPIALPGSCN10A
SCHEMBL14770483 0.80 MLKL (0.48) MLKLALPLALPIALPGSCN10A
SCHEMBL14770491 0.79 KMT2A (0.51) MLKLALPLALPIALPGBRD4
SCHEMBL12065618 0.78 MLKL (0.52) MLKLALPLALPIALPGIDO1
SCHEMBL12066567 0.78 MLKL (0.49) MLKLALPLALPIALPGIDO1
SCHEMBL12065245 0.78 ALPL (0.44) MLKLALPLALPIALPGSCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MLKL 2378/4885ALPL 4272/4885ALPI 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.